drugset / Trial / NCT01424423
NOGO-A in Multiple Sclerosis FTIH
RandomizedSequentialDouble-blindTreatment
Summary
The drug being tested in this study is GSK1223249. The drug works by inhibiting a protein that prevents nerve growth. The trial is expected to involve approximately 36 patients. The study objective is to investigate the tolerability, safety and the way the body handles GSK1223249 after a range of single doses in patients with Multiple Sclerosis (MS).
Timeline
- Start
- 2010-02-11
- Primary completion
- 2010-08-26
- Completion
- 2010-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ozanezumab | Monoclonal antibody | 0.02 mg/kg | Intravenous |
| Subject | Ozanezumab | Monoclonal antibody | 0.2 mg/kg | Intravenous |
| Subject | Ozanezumab | Monoclonal antibody | 2 mg/kg | Intravenous |
| Subject | Ozanezumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Ozanezumab | Monoclonal antibody | 30 mg/kg | Intravenous |